Status:
UNKNOWN
Assessment of Retinal Fundus Imaging Camera
Lead Sponsor:
Digital Diagnostics, Inc.
Conditions:
Diabetic Retinopathy
Diabetic Macular Edema
Eligibility:
All Genders
22+ years
Brief Summary
The goal of this prospective study is to evaluate device performance when using fundus images taken from retinal fundus cameras in subjects with and without diabetic retinopathy per ETDRS level 35 and...
Detailed Description
The goal of this prospective study is to evaluate device performance when using fundus images taken from retinal fundus cameras in subjects with and without diabetic retinopathy (ETDRS level 35 and hi...
Eligibility Criteria
Inclusion
- 22 years of age or older.
- Documented diagnosis of diabetes mellitus, as per any of the following: Having met the criteria established by the World Health Organization (WHO) and/or the American Diabetes Association (ADA), Hemoglobin A1c (HbA1c) ≥ 6.5%, Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L), Oral Glucose Tolerance Test (OGTT) with two-hour plasma glucose (2-hr PG) ≥ 200 mg/dL (11.1 mmol/L), using the equivalent of an oral 75g anhydrous glucose dose dissolved in water, Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)
- Ability to understand and the willingness to sign a written informed consent document.
- Diagnosis from a retinal specialist of ETDRS level of 35 or higher with or without DME or diagnosis from a retinal specialist of ETDRS level 20 or lower and no DME.
- Standard Corrected Visual Acuity of at least 20/40 or better in both eyes.
Exclusion
- Currently participating in an interventional eye study (e.g., actively receiving the investigational product for Diabetic Retinopathy (DR) and/or Diabetic Macular Edema (DME)).
- Has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia, or previous enucleation).
- Pregnancy
- Has a known allergy to or contraindication for the use of Tropicamide 1% or other mydriatic eye drops.
- Any condition that is contraindicated for the use of study devices in the opinion of the investigator.
- Contraindication for imaging by devices used in the study due to any of the following:
- Subject is hypersensitive to light
- Subject recently underwent photodynamic therapy (PDT)
- Subject is taking medication that causes photosensitivity
Key Trial Info
Start Date :
November 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06173232
Start Date
November 20 2023
End Date
May 1 2024
Last Update
December 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Midwest Eye Center
Cincinnati, Ohio, United States, 45202